Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teus van Laar

Showing results (11-20 of 155) with videos related to

Pageof 16
Sort By:
BMC Neurology|July 10, 2024
Correction: Comment on "Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries"Harmen R Moes, Erik Buskens, Teus van Laar
The Lancet. Neurology|August 16, 2024
Continuous subcutaneous levodopa-carbidopa infusion for Parkinson's diseaseHarmen R Moes, Erik Buskens, Teus van Laar
Movement Disorders : Official Journal of the Movement Disorder Society|October 27, 2007
Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonismAnna-Gerlind Postma, Mart Heesters, Teus van Laar
Parkinsonism & Related Disorders|April 7, 2022
Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications"Harmen R Moes, Erik Buskens, Teus van Laar
Parkinsonism & Related Disorders|June 16, 2009
Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinationsTeus van Laar, Anna G Postma, Martje Drent
Annals of Neurology|August 27, 2025
Reply to From Topography to Therapy: Rethinking Cognitive Monitoring in GBA1-Linked PDSofie Slingerland, Sygrid van der Zee, Teus van Laar
Parkinsonism & Related Disorders|December 29, 2015
Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patientsRobbert W K Borgemeester, Martje Drent, Teus van Laar
Parkinsonism & Related Disorders|May 2, 2016
Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidenceRobbert W K Borgemeester, Andrew J Lees, Teus van Laar
NPJ Parkinson'S Disease|June 26, 2024
A retrospective study of the MDS criteria for prodromal Parkinson's disease in the general populationGijs W de Klerk, Teus van Laar, Sanne K Meles
Nederlands Tijdschrift Voor Geneeskunde|October 28, 2010
[Rasagiline is not for all Parkinson disease patients: the ADAGIO study]Teus van Laar, Agnita J W Boon, Bastiaan R Bloem
Pageof 16

Showing results (11-20 of 155) with videos related to

Sort By:
Pageof 16
BMC Neurology|July 10, 2024
Correction: Comment on "Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries"Harmen R Moes, Erik Buskens, Teus van Laar
The Lancet. Neurology|August 16, 2024
Continuous subcutaneous levodopa-carbidopa infusion for Parkinson's diseaseHarmen R Moes, Erik Buskens, Teus van Laar
Movement Disorders : Official Journal of the Movement Disorder Society|October 27, 2007
Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonismAnna-Gerlind Postma, Mart Heesters, Teus van Laar
Parkinsonism & Related Disorders|April 7, 2022
Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications"Harmen R Moes, Erik Buskens, Teus van Laar
Parkinsonism & Related Disorders|June 16, 2009
Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinationsTeus van Laar, Anna G Postma, Martje Drent
Annals of Neurology|August 27, 2025
Reply to From Topography to Therapy: Rethinking Cognitive Monitoring in GBA1-Linked PDSofie Slingerland, Sygrid van der Zee, Teus van Laar
Parkinsonism & Related Disorders|December 29, 2015
Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patientsRobbert W K Borgemeester, Martje Drent, Teus van Laar
Parkinsonism & Related Disorders|May 2, 2016
Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidenceRobbert W K Borgemeester, Andrew J Lees, Teus van Laar
NPJ Parkinson'S Disease|June 26, 2024
A retrospective study of the MDS criteria for prodromal Parkinson's disease in the general populationGijs W de Klerk, Teus van Laar, Sanne K Meles
Nederlands Tijdschrift Voor Geneeskunde|October 28, 2010
[Rasagiline is not for all Parkinson disease patients: the ADAGIO study]Teus van Laar, Agnita J W Boon, Bastiaan R Bloem
Pageof 16